Revamped French agency to put the emphasis on post-authorisation monitoring
This article was originally published in Scrip
Executive Summary
France's restructured regulatory agency, which is expected to be fully operational in its new incarnation by next spring, will be putting the emphasis firmly on the post-authorisation monitoring of the safety and efficacy of medicines and other health products.